Research programme: glucocorticoid receptor agonists - AstraZeneca/Bayer Schering Pharma

Drug Profile

Research programme: glucocorticoid receptor agonists - AstraZeneca/Bayer Schering Pharma

Alternative Names: SEGRAs - AstraZeneca/Bayer Schering Pharma; WC 3027

Latest Information Update: 24 Mar 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer Schering Pharma
  • Developer AstraZeneca; Warner Chilcott
  • Class Glucocorticoids
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Inflammation; Respiratory tract disorders

Most Recent Events

  • 12 Apr 2007 Data presented at the 233rd American Chemical Society National Meeting (ACS-2007) added to the Inflammation pharmacodynamics section
  • 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG
  • 09 Sep 2004 Preclinical trials in Inflammation in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top